Lilly Receives FDA Breakthrough Therapy Designation for Baricitinib for the Treatment of Alopecia Areata (March 16, 2020).
Recognition reinforces baricitinib’s potential to be the first FDA-approved medicine for individuals living with alopecia areata.
Lilly Receives FDA Breakthrough Therapy Designation for Baricitinib for the Treatment of Alopecia Areata